Literature DB >> 18839218

Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates.

Ari Auron1, Leyat Tal, Tarak Srivastava, Uri S Alon.   

Abstract

We present the details of three children with hypercalcemia-induced acute kidney injury (AKI). After traditional therapy with fluids, loop diuretics, steroids and calcitonin had failed to correct the hypercalcemia, they were given treatment with low doses of intravenous (i.v.) pamidronate, which resulted in normalization of serum calcium and kidney function. In one child Doppler renal ultrasound revealed dampened arterial blood flow, which resolved with normalization of serum calcium. On the basis of cumulative data and our experience, we suggest that i.v. application of bisphosphonates be moved from the second to the first line of treatment of hypercalcemic AKI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839218     DOI: 10.1007/s00467-008-1011-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  23 in total

1.  Renal failure with the use of zoledronic acid.

Authors:  Jennie T Chang; Lanh Green; Julie Beitz
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

Review 2.  Clinical practice. Hypercalcemia associated with cancer.

Authors:  Andrew F Stewart
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

3.  Intravenous pamidronate sodium therapy in immobilization-related hypercalcemia.

Authors:  F Tamion; F Bonmarchand; C Girault; V Chevron; J Leroy
Journal:  Clin Nephrol       Date:  1995-02       Impact factor: 0.975

4.  Safety of pamidronate in patients with renal failure and hypercalcemia.

Authors:  C E Machado; C D Flombaum
Journal:  Clin Nephrol       Date:  1996-03       Impact factor: 0.975

5.  Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis.

Authors:  Nathalie Alos; Dardye Eugène; Marc Fillion; Julie Powell; Victor Kokta; Gilles Chabot
Journal:  Horm Res       Date:  2006-04-06

6.  Aminoglycoside antibiotics induce pH-sensitive activation of the calcium-sensing receptor.

Authors:  Stuart McLarnon; Darren Holden; Donald Ward; Malcolm Jones; Austin Elliott; Daniela Riccardi
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

Review 7.  Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.

Authors:  Debasish Banerjee; Arif Asif; Liliane Striker; Richard A Preston; Jacques J Bourgoignie; David Roth
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

8.  The use of pamidronate in three children with renal disease.

Authors:  E Sellers; A Sharma; C Rodd
Journal:  Pediatr Nephrol       Date:  1998-11       Impact factor: 3.714

Review 9.  Management of the adverse effects associated with intravenous bisphosphonates.

Authors:  T Tanvetyanon; P J Stiff
Journal:  Ann Oncol       Date:  2006-03-17       Impact factor: 32.976

10.  Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.

Authors:  P L Selby; M Davies; J S Marks; E B Mawer
Journal:  Clin Endocrinol (Oxf)       Date:  1995-11       Impact factor: 3.478

View more
  2 in total

Review 1.  Hypercalcemia: a consultant's approach.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2017-09-06       Impact factor: 3.714

2.  Resection of granulomatous tissue resolves silicone induced hypercalcemia.

Authors:  Beatrice J Edwards; Smita Saraykar; Ming Sun; William A Murphy; Pei Lin; Robert Gagel
Journal:  Bone Rep       Date:  2015-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.